Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T60405
|
||||
| Former ID |
TTDC00310
|
||||
| Target Name |
mRNA of RAF proto-oncogene serine/threonine-protein kinase
|
||||
| Gene Name |
RAF1
|
||||
| Synonyms |
C-RAF; CRaf; Raf kinase; Raf-1; RAF1
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
| Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
| Diabetic macular edema; Diabetic retinopathy [ICD9: 250, 250.5, 362.0-362.2, 362.01, 362.07, 362.53, 782.3; ICD10: E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35-H35.2, H35.8, H36] | |||||
| Melanoma [ICD9: 172; ICD10: C43] | |||||
| Parkinson's disease [ICD9: 332; ICD10: G20] | |||||
| Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
| Function |
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2- antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. PhosphorylatesPPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2),apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.
|
||||
| BioChemical Class |
Target of antisense drug
|
||||
| Target Validation |
T60405
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.11.1
|
||||
| Sequence |
MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRV
FLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAAS LIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKV PTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTF NTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNL SPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSF GTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIV TQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGL TVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYE LMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFP QILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF |
||||
| Drugs and Mode of Action | |||||
| Inhibitor | 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid | Drug Info | [528356] | ||
| 6-Benzylsulfanyl-9H-purine | Drug Info | [527421] | |||
| 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine | Drug Info | [527421] | |||
| BIIB-024 | Drug Info | [543571] | |||
| DEBROMOHYMENIALDISINE | Drug Info | [526243] | |||
| GW-5074 | Drug Info | [526991] | |||
| L-790070 | Drug Info | [529561] | |||
| MLN2480 | Drug Info | [550478] | |||
| PLX-ORI3 | Drug Info | [543571] | |||
| SPN-803 | Drug Info | [543571] | |||
| ZM-336372 | Drug Info | [529039] | |||
| Modulator | RG7304 | Drug Info | [551608] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| BioCyc Pathway | MAP kinase cascade | ||||
| KEGG Pathway | MAPK signaling pathway | ||||
| ErbB signaling pathway | |||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Chemokine signaling pathway | |||||
| FoxO signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Gap junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| B cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| Fc gamma R-mediated phagocytosis | |||||
| Long-term potentiation | |||||
| Neurotrophin signaling pathway | |||||
| Serotonergic synapse | |||||
| Long-term depression | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin signaling pathway | |||||
| GnRH signaling pathway | |||||
| Progesterone-mediated oocyte maturation | |||||
| Estrogen signaling pathway | |||||
| Melanogenesis | |||||
| Prolactin signaling pathway | |||||
| Thyroid hormone signaling pathway | |||||
| Oxytocin signaling pathway | |||||
| Alcoholism | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Influenza A | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Colorectal cancer | |||||
| Renal cell carcinoma | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Bladder cancer | |||||
| Chronic myeloid leukemia | |||||
| Acute myeloid leukemia | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancer | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| EGFR1 Signaling Pathway | |||||
| PANTHER Pathway | Angiogenesis | ||||
| B cell activation | |||||
| EGF receptor signaling pathway | |||||
| Endothelin signaling pathway | |||||
| FGF signaling pathway | |||||
| Inflammation mediated by chemokine and cytokine signaling pathway | |||||
| Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||||
| Integrin signalling pathway | |||||
| Interleukin signaling pathway | |||||
| PDGF signaling pathway | |||||
| T cell activation | |||||
| VEGF signaling pathway | |||||
| Ras Pathway | |||||
| Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
| Endothelins | |||||
| BCR signaling pathway | |||||
| GMCSF-mediated signaling events | |||||
| Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||||
| CDC42 signaling events | |||||
| SHP2 signaling | |||||
| mTOR signaling pathway | |||||
| IL2-mediated signaling events | |||||
| IGF1 pathway | |||||
| Ras signaling in the CD4+ TCR pathway | |||||
| Ceramide signaling pathway | |||||
| ErbB1 downstream signaling | |||||
| ErbB2/ErbB3 signaling events | |||||
| PDGFR-beta signaling pathway | |||||
| p38 signaling mediated by MAPKAP kinases | |||||
| Nongenotropic Androgen signaling | |||||
| Internalization of ErbB1 | |||||
| CXCR3-mediated signaling events | |||||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| Trk receptor signaling mediated by the MAPK pathway | |||||
| Downstream signaling in na& | |||||
| #xef | |||||
| ve CD8+ T cells | |||||
| Regulation of retinoblastoma protein | |||||
| Signaling events mediated by focal adhesion kinase | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| Insulin Signalling | |||||
| Reactome | Stimuli-sensing channels | ||||
| GP1b-IX-V activation signalling | |||||
| CREB phosphorylation through the activation of Ras | |||||
| CD209 (DC-SIGN) signaling | |||||
| RAF activation | |||||
| MAP2K and MAPK activation | |||||
| Negative feedback regulation of MAPK pathway | |||||
| Negative regulation of MAPK pathway | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| TCR Signaling Pathway | |||||
| Senescence and Autophagy in Cancer | |||||
| EPO Receptor Signaling | |||||
| Regulation of Actin Cytoskeleton | |||||
| IL-2 Signaling Pathway | |||||
| Insulin Signaling | |||||
| EGF/EGFR Signaling Pathway | |||||
| MAPK Cascade | |||||
| MAPK Signaling Pathway | |||||
| TGF beta Signaling Pathway | |||||
| Signaling of Hepatocyte Growth Factor Receptor | |||||
| Kit receptor signaling pathway | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| IL-3 Signaling Pathway | |||||
| Cardiac Hypertrophic Response | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| RAF/MAP kinase cascade | |||||
| Iron uptake and transport | |||||
| Nanoparticle-mediated activation of receptor signaling | |||||
| PDGF Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| BDNF signaling pathway | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Oncostatin M Signaling Pathway | |||||
| Corticotropin-releasing hormone | |||||
| Interleukin-11 Signaling Pathway | |||||
| AGE/RAGE pathway | |||||
| TNF alpha Signaling Pathway | |||||
| B Cell Receptor Signaling Pathway | |||||
| Prostate Cancer | |||||
| Signaling Pathways in Glioblastoma | |||||
| Endothelin Pathways | |||||
| TWEAK Signaling Pathway | |||||
| FSH signaling pathway | |||||
| Leptin signaling pathway | |||||
| Rap1 signalling | |||||
| Integrin-mediated Cell Adhesion | |||||
| GP1b-IX-V activation signalling | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| IL-5 Signaling Pathway | |||||
| References | |||||
| Ref 521624 | ClinicalTrials.gov (NCT00100672) Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer. U.S. National Institutes of Health. | ||||
| Ref 523603 | ClinicalTrials.gov (NCT01425008) Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma. U.S. National Institutes of Health. | ||||
| Ref 527280 | Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 1;10(21):7244-51. | ||||
| Ref 548872 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029757) | ||||
| Ref 526243 | J Med Chem. 2002 Jan 17;45(2):529-32.Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). | ||||
| Ref 526991 | Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. | ||||
| Ref 526998 | Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53. | ||||
| Ref 527421 | J Med Chem. 2005 Feb 10;48(3):710-22.Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. | ||||
| Ref 528356 | Bioorg Med Chem Lett. 2006 Oct 15;16(20):5378-83. Epub 2006 Aug 4.Aza-stilbenes as potent and selective c-RAF inhibitors. | ||||
| Ref 529039 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. | ||||
| Ref 529561 | J Med Chem. 2008 Jul 24;51(14):4122-49. Epub 2008 Jun 26.Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. | ||||
| Ref 543571 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). | ||||
| Ref 549605 | US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. | ||||
| Ref 551023 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | ||||
| Ref 551051 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.